Marksans Pharma Limited (BOM:524404)
249.95
-2.00 (-0.79%)
At close: May 28, 2025
Marksans Pharma Revenue
In the fiscal year ending March 31, 2025, Marksans Pharma had annual revenue of 26.23B INR with 20.46% growth. Marksans Pharma had revenue of 7.08B in the quarter ending March 31, 2025, with 26.51% growth.
Revenue
26.23B
Revenue Growth
+20.46%
P/S Ratio
4.32
Revenue / Employee
22.99M
Employees
1,141
Market Cap
113.41B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 26.23B | 4.45B | 20.46% |
Mar 31, 2024 | 21.77B | 3.25B | 17.56% |
Mar 31, 2023 | 18.52B | 3.61B | 24.23% |
Mar 31, 2022 | 14.91B | 1.15B | 8.33% |
Mar 31, 2021 | 13.76B | 2.42B | 21.32% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,646.93B |
HDFC Bank | 2,728.47B |
Tata Consultancy Services | 2,553.24B |
Bharti Airtel | 1,729.85B |
ICICI Bank | 2,006.54B |
State Bank of India | 3,429.39B |
Infosys | 1,647.16B |
Bajaj Finance | 369.88B |
Marksans Pharma News
- 14 days ago - Marksans Pharma’s UK subsidiary Relonchem gets UKMHRA nod for Gabapentin oral solution - Business Upturn
- 4 weeks ago - Marksans Pharma’s subsidiary receives one USFDA observation after cGMP inspection at New York facility - Business Upturn
- 3 months ago - Marksans Pharma’s subsidiary Relonchem gets UK approval for Ibuprofen and Paracetamol tablets - Business Upturn
- 6 months ago - Marksans Pharma shares jump 2% following USFDA approval for Loratadine Tablets USP 10 mg - Business Upturn
- 6 months ago - Marksans Pharma receives USFDA approval for Loratadine Tablets USP 10 mg - Business Upturn
- 6 months ago - Marksans Pharma Ltd (BOM:524404) Q2 FY25 Earnings Call Highlights: Strong Revenue Growth and ... - GuruFocus
- 7 months ago - Marksans Pharma shares jump over 3% on Q2 results - Business Upturn
- 7 months ago - Marksans Pharma Q2 FY25: Revenue up 20.84% YoY to Rs 641.92 crore, Net Profit up 16.56% YoY - Business Upturn